Patients From trial design for patients to trial design with patients... At the 2022 Drug Information Association (DIA) annual meeting last week, it was
Views & Analysis A healthy discussion on funding tomorrow’s treatments The adage 'do more with less' is of increasing relevance to global economies, with governments under pressure to cut and compress public spend yet simultaneously increase both productivity and
Views & Analysis Precision medicine and data science: the ‘new normal’ for dr... Balancing innovation and huge unmet patient need with burgeoning cost constraints.
News Summit climbs on rumour of $15bn AstraZeneca interest Is AstraZeneca about to join the ranks of pharma companies spending big bucks on PD(L)-1xVEGF bispecific antibodies for cancer?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
